UBS downgraded Rollins to Neutral from Buy with an unchanged price target of $49. The analyst says potential shifts in the company’s growth and margin narratives are creating a more balanced setup in the coming months. Rollins’ outgrowth versus peer Rentokil could narrow in upcoming quarters, the analyst tells investors in a research note. UBS says that while Rollins’ fundamentals are solid, the setup is now more balanced.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
